MOUNJARO®
(tirzepatide)
ELI LILLY
HK Reg. No. HK-68408 – HK-68413 (14 Oct, 2024)
Composition:1
• Available as solution for injection (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg of tirzepatide per 0.6 mL in pre-filled pen)
Indication:1
• Type 2 diabetes mellitus
Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
° as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
° in addition to other medicinal products for the treatment of diabetes
• Weight management
Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of
° ≥ 30 kg/m2 (obesity) or
° ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus)
References
1. EMA. Mounjaro Summary of Product Characteristics. 25 October 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf [Accessed 6 November 2024].
2. FDA. ALTUVIIIO® Highlights of Prescribing Information. May 2024. Available from: https://www.fda.gov/media/165594/download. [Accessed 6 November 2024].
3. FDA. TEVIMBRA® Highlights of Prescribing Information. March 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf [Accessed 7 November 2024].
